NICE Recommends BioMarin’s Vimizim® (elosulfase alfa)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NICE Recommends BioMarin’s Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England

SAN RAFAEL, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that The National Institute for Health and Care Excellence (NICE), NHS England and BioMarin have reached an agreement on a Managed Access Agreement, which provides a basis for access for clinically suitable mucopolysaccharidosis type IVA (MPS IVA) patients to Vimizim ® (elosulfase alfa) treatment for the next five years. The provision of access is subject to the completion of the ongoing NICE Highly Specialised Technologies process, where the final guidance is expected in mid-December. 

“The Morquio A community has been long awaiting this decision, which provides patients access to Vimizim, and we are relieved and elated to have resolution,” said Christine Lavery, Chief Executive of the MPS Society. “With fewer than 80 people living with Morquio A syndrome in England, it is hard to comprehend what these patients and their families have been through over the last 18 months. Treatment to this community is so much more than just a therapy. It is hope for a future where their improved health allows them to reach their full potential.”

Morquio A syndrome is an ultra-rare, severely debilitating disease affecting an estimated 3,000 patients in the developed world. The most common features of the disease are progressive skeletal dysplasia, the need for frequent surgical procedures related primarily to musculoskeletal or respiratory dysfunction, and significant limitations in mobility, endurance, and breathing.

“This is fantastic news for all affected patients,” said Professor Chris Hendriksz of Salford Royal NHS Foundation Trust. “Many of the patients who participated in the largest ever clinical trial for ultra rare enzyme replacement therapies are from England, and today’s announcement means they and all diagnosed patients in the country will now have a greater opportunity to access treatment.  The decision by NICE also means many patients will have the possibility of access to treatment at home, which will put an end to long journeys to hospital to receive weekly treatment. The impact for patients will be significant. Previously, we have only been able to help manage symptoms, but this new treatment is now able to target the underlying cause of this devastating disorder.”

“As Vimizim is the first and only treatment to address the underlying cause of Morquio A syndrome, we applaud the NICE’s decision to provide the patient community with access to this much-needed therapy,” said Jim Lennertz, Group Vice President and Regional Manager of Europe, the Middle East and Africa at BioMarin. “As part of our commitment to the MPS community, we worked diligently with the NICE, advocates and patients to bring Vimizim to those who need it.”

The U.S. Food and Drug Administration (FDA) approved the Vimizim license application for the treatment of patients with Morquio A syndrome on February 14, 2014, and the European Commission approved it on April 28, 2014.  The therapy is also approved in Australia, Canada, Brazil and Japan.

About Vimizim

Vimizim (elosulfase alfa) is a treatment for patients with Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA). Vimizim is the first approved enzyme replacement therapy (ERT) designed to target the underlying cause of Morquio A syndrome—a deficiency in the enzyme N-acetylgalactosamine-6 sulfatase (GALNS). Vimizim is intended to provide the exogenous enzyme GALNS that will be taken up into the lysosomes and increase the catabolism of GAGs. Morquio A syndrome is a rare, severely debilitating and progressive disease that previously had no approved, standard-of-care treatment other than supportive care.

Important Safety Information

Life-threatening allergic reactions, known as anaphylaxis, can occur during Vimizim® (elosulfase alfa) infusions. Due to the potential for anaphylaxis, appropriate medical support should be readily available when Vimizim is administered and for an appropriate period of time following administration.

Hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion. Frequent symptoms of hypersensitivity reactions included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing. Because of the potential for hypersensitivity reactions, administer antihistamines with or without antipyretics prior to infusion.  If severe hypersensitivity reactions occur, immediately stop the infusion of Vimizim and initiate appropriate treatment. Patients with acute febrile or respiratory illness at the time of Vimizim infusion may be at higher risk of life-threatening complications from hypersensitivity reactions.

Sleep apnea is common in MPS IVA patients. Evaluation of airway patency should be considered prior to initiation of treatment with Vimizim. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an acute reaction, or extreme drowsiness/sleep induced by antihistamine use.

Spinal or cervical cord compression (SCC) is a known and serious complication of MPS IVA and may occur as part of the natural history of the disease. In clinical trials, SCC was observed both in patients receiving Vimizim and patients receiving placebo. Patients with MPS IVA should be monitored for signs and symptoms of SCC (including back pain, paralysis of limbs below the level of compression, urinary and fecal incontinence) and given appropriate clinical care. All patients treated with Vimizim 2 mg/kg once per week in the placebo-controlled trial developed anti-drug antibodies.

Vimizim should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known if Vimizim is present in human milk.

Safety and effectiveness in paediatric patients below 5 years of age have not been established. In clinical trials, the most common adverse reactions (≥10%) occurring during infusion included pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue. The acute reactions requiring intervention were managed by either temporarily interrupting or discontinuing infusion, and administering additional antihistamine, antipyretics, or corticosteroids.

Please see full prescribing information, including boxed warning, or visit www.VIMIZIM.com . The Summary of Product Characteristics can be found at:  http://www.ema.europa.eu/docs/en_GB/document_...169239.pdf .

About Morquio A Syndrome

Morquio A syndrome, or Mucopolysaccharidosis IVA (MPS IVA) is a disease in which people are missing an enzyme essential in the breakdown and removal of the glycosaminoglycans (GAGs) called keratan sulfate (KS) and chondroitin-6-sulfate (C6S). The incompletely broken down GAGs remain stored in cells in the body causing progressive damage. This excessive storage causes systemic skeletal dysplasia, short stature, and joint abnormalities, limiting mobility and endurance. Malformation of the chest impairs respiratory function, and looseness of joints in the neck causing spinal instability and potentially spinal cord compression. Other symptoms may include hearing loss, corneal clouding, and heart disease. Initial symptoms often become evident in the first five years of life. The disease substantially limits both the quality and length of life of those affected. The rate of incidence of Morquio A syndrome is as yet unconfirmed and varies among different populations, and estimates vary between 1 in 200,000 live births and 1 in 450,000 live births.

About BioMarin

BioMarin is a global biotechnology company that develops and commercialises innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialised products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com .

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expectations regarding NICE, NHS England and BioMarin reaching an agreement on a Managed Access Agreement for reimbursement for Vimizim.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the provision of access is subject to the completion of the ongoing NICE Highly Specialised Technologies process, actual reimbursement decisions by NHS England; the acceptability of final terms of the Managed Access Agreement; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2014 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, and Vimizim® are registered trademarks of BioMarin Pharmaceutical Inc.

Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Judith Moore On behalf of BioMarin Pharmaceutical Inc. +44 (0)20 7632 1806

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 8

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 101

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 10

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 99

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 159

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 229

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into National HealthCare Corporation by Kaskela Law

Updated Category News Views 203

Kaskela Law LLC Announces Investigation Kaskela Law LLC has recently launched an investigation into National HealthCare Corporation (NYSE: NHC) on behalf of its shareholders. This inquiry seeks to determine if the company or its executives have violated securities laws or breached their fiduciary duties in light of recent corporate actions. Investigation Objectives The...

Continue Reading
HOPE Therapeutics Expands Its Reach in Florida’s Mental Health Care

Updated Category News Views 161

HOPE Therapeutics Welcomes Cohen & Associates to the Network In an exciting advancement, HOPE Therapeutics, Inc. has recently integrated Cohen & Associates, LLC into its expanding professional framework, aimed at revolutionizing the landscape of interventional psychiatry. This noteworthy inclusion signals a meaningful step in enhancing mental health services across...

Continue Reading
Abdullah Abdin Ready Mix Concrete's Historic Certification Milestone

Updated Category News Views 217

Abdullah Abdin Ready Mix Concrete Announces Historic Achievement Setting new standards in sustainability and innovation, Abdullah Abdin Ready-Mix Concrete has proudly achieved the prestigious Concrete Sustainability Council (CSC) certification. This recognition establishes the company as the first ready-mix concrete firm in the MENA region to receive such an influential...

Continue Reading
The Tragic Shooting of Charlie Kirk: National Outrage Ensues

Updated Category News Views 393

The Shocking Assassination of Charlie Kirk Conservative political activist Charlie Kirk was tragically shot and killed while addressing a gathering. This shocking incident has ignited a series of investigations and public responses, leading to numerous political reactions across the nation. Details Surrounding the Incident The violent act took place during Kirk's speech,...

Continue Reading
Cibus Global Ltd. Faces Market Challenges with Stock Dip

Updated Category News Views 129

Cibus Global Ltd. Faces Significant Stock Decline In recent trading sessions, Cibus Global Ltd. (CBUS) stock encountered a dramatic decline, hitting a 52-week low of $2.36. This notable drop is stark when compared to its previous high of $23.18, showing a staggering reduction of approximately 88.48% over the past year. The plummeting share price has raised alarms among...

Continue Reading